The treatment being tested includes two investigational products, PP1493 and PP1815, which are bacteriophage solutions given through intra-articular injection (injection directly into the joint). These will be compared to a placebo treatment, with both groups also receiving standard surgical care. The study aims to determine if adding bacteriophage therapy to standard treatment is safe and effective for treating prosthetic joint infections.

The study will monitor patients for three months to assess their response to treatment. Participants will receive either the bacteriophage treatment or placebo, along with standard care. During the study, doctors will track the healing of the infection and monitor for any side effects. The treatment period lasts for three days, with follow-up evaluations continuing for several months to ensure patient safety and assess treatment effectiveness.

The purpose of the study is to compare how these antibiotics impact the variety of bacteria in the gut over a short period, specifically from the first day to the fifth day of treatment. This is important because antibiotics can sometimes disrupt the balance of bacteria in the gut, which can lead to other health issues. The study will involve patients who are suspected of having an infection related to their prosthetic or other medical equipment. The diversity of each patient’s gut bacteria will be analyzed using a method called 16S rDNA metagenomics, which is a way to study the genetic material of bacteria to understand their variety and abundance.

Participants in the study will receive one of the antibiotic treatments mentioned above, or a combination of them, for a maximum of five days. The study will help researchers understand which antibiotic or combination of antibiotics is most effective in treating these infections while having the least impact on the gut bacteria. This information could lead to better treatment strategies for patients with bone and joint infections related to medical equipment.

The purpose of the study is to understand how clindamycin is processed in the body and how effective it is when used alone or in combination with rifampicin. Participants will receive either clindamycin by itself or a combination of clindamycin and rifampicin. The study will monitor how the body absorbs and eliminates clindamycin, as well as the overall effectiveness of the treatment in curing the infections.

Participants will take the medication orally, and the study will last for a period of up to 12 weeks. The trial aims to gather information on how well the treatment works and to identify any factors that might influence its success, such as the participant’s weight or the use of additional medications like rifampicin. The ultimate goal is to improve treatment strategies for these infections.

The research will evaluate two experimental treatments called PP1493 and PP1815, which are special solutions containing bacteriophages that are given through injection or infusion. These will be compared to treatment with a sodium chloride solution (salt water). All patients in the study will also receive standard antibiotic treatment and a surgical procedure called DAIR (debridement, antibiotics, and implant retention) to clean the infected joint area.

The main goal is to determine how well these treatments control the infection by monitoring signs like fever, pain, and swelling around the joint. The study will track whether the infection goes away and stays away after treatment. Patients will be followed for several months to check their recovery and any potential side effects of the treatment.

The purpose of the study is to determine how accurate the 68 Gallium citrate PET/CT scan is in diagnosing chronic infections in artificial hip or knee joints. Participants in the study will undergo this imaging procedure to see if it can reliably identify infections. The study will also compare the results of the 68 Gallium citrate PET/CT scan with another imaging method called marked polynuclear scintigraphy to evaluate which method is more effective.

Throughout the study, researchers will assess the accuracy of the 68 Gallium citrate PET/CT scan by looking at its ability to correctly identify infections. They will also examine how consistent the results are when interpreted by different observers. The study aims to provide valuable information that could improve the diagnosis of infections in people with artificial joints, potentially leading to better treatment outcomes.

The antibiotics being tested in this study are Vancomycin and Tobramycin. These are medicines used to treat infections caused by bacteria. The study will compare the effects of the antibiotic-treated bone graft with a placebo-treated bone graft. A placebo is a substance with no active medication, used to compare the effects of the actual treatment. The study will observe if there is a difference in the rate of infections between the two groups over a period of two years.

Participants in the study will receive either the antibiotic-treated bone graft or the placebo-treated bone graft during their hip replacement surgery. The study will monitor the participants for any signs of infection or need for additional surgery in the same hip joint within two years. It will also look at the time and reasons for any further surgeries or implant revisions within two to five years. The study aims to provide valuable information on whether the antibiotic-treated bone graft can effectively reduce the risk of infection after hip replacement surgery.

Participants in the study will receive treatment for up to 12 weeks. The study will compare rifampicin with other antibiotics, including amoxicillin, moxifloxacin, clindamycin, and doxycycline, to see how well they work in managing the infection. Some participants may receive a placebo. The study will monitor the participants for any signs of the infection returning or new infections developing, as well as any side effects from the medications.

The goal is to gather information over a period of time to determine the best treatment approach for managing Cutibacterium acnes infections in joint replacements. The study will also look at how often these infections fail to be managed successfully and any adverse effects linked to the use of rifampicin. Participants will be followed up for up to 24 months to assess the long-term outcomes of the treatment.

The purpose of the study is to see if using a method called Minimum Biofilm Eradication Concentration (MBEC) along with another method called Minimum Inhibitory Concentration (MIC) can help guide the treatment of these infections more effectively. The study will compare how these methods affect the resolution of the infection, the body’s tolerance to the drugs, and the patterns of resistance that might develop in the bacteria causing the infection. Participants in the study will receive one of the antibiotics mentioned, or a placebo, and their progress will be monitored over a period of time.

Throughout the study, participants will be observed for up to 12 months to track various outcomes, such as the need for additional procedures, the recurrence of infection, and overall health status. The study will also look at the resources used during treatment, such as hospital stays and outpatient visits, and the costs associated with these. The goal is to find the most effective way to treat periprosthetic joint infections and improve patient outcomes.